Solid Biosciences Inc.
corporate_fare Company Profile
Solid Biosciences Inc. (NASDAQ:SLDB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SLDB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for SLDB spans 10-Q, SCHEDULE 13D/A, 8-K, PRE 14A.
Recent high-impact activity:
- Solid Bio Posts $53.9M Q3 Loss, Sets Late-Q4 FDA Meeting on Duchenne Gene Therapy
- Solid Biosciences Q3 Loss Widens to $53.9M; $348.9M Cash Funds Runway Into 1H 2028
- Perceptive Advisors Lifts Solid Biosciences Stake to 11.2% with $0.001 Pre-Funded Warrants
- Solid Biosciences Replaces Exhausted $85M ATM with New $200M Equity Program
- Solid Biosciences Q2 Loss Widens to $54.8M, Cash Runway Extended to Mid-2028
Financial Snapshot
Short Interest & Short Volume
10.71 days to coverFINRA reported short interest of 13,303,890 shares in SLDB as of the October 30, 2026 settlement, a 8.2% increase from the prior period — about 10.7 days to cover at its recent average daily volume. On November 20, 2026, 71.4% of SLDB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SLDB, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
New $200M ATM Program Established · Prior $85M ATM Fully Drawn
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →